Oxidative status and malondialdehyde in β-thalassaemia patients

European Journal of Clinical Investigation

Volumn 32, Issue SUPPL. 1, 2002, Pages 55-60

  Cighetti, Giuliana ^a   Duca, L ^a   Bortone, L ^a   Sala, S ^a   Nava, I ^a   Fiorelli, G ^a   Cappellini, M D ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Iron overload; Malondialdehyde; Nontransferrin bound iron; Thalassaemia

Indexed keywords

ANTIOXIDANT; BETA GLOBIN; DEFEROXAMINE; FERRITIN; IRON; IRON BINDING PROTEIN; MALONALDEHYDE; PEROXY RADICAL; TRANSFERRIN; IRON CHELATING AGENT; PEROXIDE;

ARTICLE; BETA THALASSEMIA; BLOOD SAMPLING; CHELATION THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FERRITIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; OXIDATIVE STRESS; PRIORITY JOURNAL; THALASSEMIA MAJOR; TRANSFUSION; ADULT; BLOOD; FEMALE; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; ANTIOXIDANTS; BETA-THALASSEMIA; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIDES; TRANSFERRIN;

EID: 3242780446     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.0320s1055.x     Document Type: Article

References (24)

1. Scott MD, van der Berg JJM, Repka T, Rouyer-Fessard P, Hebbel RP, Beuzard P, et al. Effect of excess alpha-hemoglobin chains on cellular and membrane oxidation in model beta-thalassemic erythrocytes. J Clin Invest 1993;91:1706-12.
2. Gutteridge JMC, Rowley DA, Griffiths E, Haliwell B. Low molecular weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci 1985;68:463-7.
3. Hageman JJ, Bast A, Vermeulen N. Monitoring of oxidative free radical damage in vivo: analytical aspects. Chem-Biol Interact 1982;82:243-93.
4. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Rad Biol Med 1991;11:81-128.
5. Houglum K, Pilip M, Witztum JL, Chojkier M. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J Clin Invest 1990;86:1991-8.
6. Draper HH, Hadley M, Lissemore NM, Cole PD. Identification of N-ε-(2-propenal) lysine as a major urinary metabolite of malondialdehyde. Lipids 1988;23:626-8.
7. Livrea MA, Tesoriere L, Pintaudi AM, Calabrese A, Maggio A, Freisleben HJ, et al. Oxidative stress and antioxidant status in β-thalassemia major: iron overload and depletion of lipid-soluble antioxidants. Blood 1996;88:3608-14.
8. Suttnar J, Cermak J, Dyr JE. Solid-phase extraction in malondialdehyde analysis. Anal Biochem 1997;249:20-3.
9. Nair V, Turner GA. The thiobarbituric acid test for lipid peroxidation: structure of the adduct with malondialdehyde. Lipids 1984;19:804-5.
10. Cighetti G, Debiasi S, Paroni R, Allevi P. Free and total malondialdehyde assessment in biological matrices by gas chromatography-mass spectrometry. Anal Biochem 1999;266:222-9.
11. Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD. Membrane-bound iron contributes to oxidative damage of β-thalassemia intermedia erythrocytes. Br J Haematol 2000;111:1-4.
12. Dobbin PS, Hider RC, Hall AD, Taylor PD, Sarpong P, Porter JB, et al. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4 (1H)-pyridinones: orally active iron chelators with clinical potential. J Med Chem 1993;36:2448-58.
13. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci PM. Venous thromboembolism and hypercoaugulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000;111:467-73.
14. Camaschella C, Mazza U, Roetto A, Gottardi E, Parziale A, Travi M, et al. Genetic interaction in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-protometers, and beta-LCR hypersensitive sites 2 and 4 in Italian patients. Am J Hematol 1995;48:82-7.
15. 2]-2-propenal). J Labelled Compd Radiopharm 1994;34:557-63.
16. Cighetti G, Debiasi S, Ciuffreda P, Allevi P. β-Ethoxyacrolein contamination increases malondialdehyde inhibition of milk xanthine oxidase activity. Free Rad Biol Med 1998;25:818-25.
17. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 1996;88:705-13.
18. Valkonen M, Kuusi T. Spectrophotometric assay for total peroxyl radical-trapping antioxidant potential in human serum. J Lipid Res 1997;38:823-33.
19. Scott MD, Eaton JW. Thalassaemic erythrocytes: cellular suicide arising from iron and glutathione-dependent oxidation reactions? Br J Haematol 1995;91:811-9.
20. Giardini O, Cantani A, Donfrancesco A, Martino F, Mandarino O, D'Eufemia P, et al. Biochemical and clinical effects of vitamin E administration in homozygous beta-thalassemia. Acta Vitaminol Enzymol 1985;7:55.
21. Knight JA, Searles DA, Clayton FC. The effect of desferrioxamine on stored erythrocytes-lipid peroxidation, deformability, and morphology. An Clin Lab Sci 1996;26:283-90.
22. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci 1988;85:9748-52.
23. Prior RL, Cao G. In vivo antioxidant capacity: comparison of different analytical methods. Free Rad Biol Med 1999;27:1173-81.
24. Ghiselli A, Serafini M, Maiani G, Azzimi E, Ferro-Luzzi A. A fluorescence-based method for measuring total plasma antioxidant capacity. Free Rad Biol Med 1995;18:29-36.25.